Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Liabilities (2016 - 2026)

Cytosorbents filings provide 16 years of Total Liabilities readings, the most recent being $38.3 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 5.55% to $38.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.3 million, a 5.55% increase, with the full-year FY2025 number at $38.3 million, up 5.55% from a year prior.
  • Total Liabilities hit $38.3 million in Q4 2025 for Cytosorbents, up from $36.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $38.3 million in Q4 2025 to a low of $10.2 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $27.9 million (2022), compared with a mean of $29.2 million.
  • Biggest five-year swings in Total Liabilities: crashed 55.4% in 2021 and later surged 172.44% in 2022.
  • Cytosorbents' Total Liabilities stood at $26.9 million in 2021, then grew by 3.4% to $27.9 million in 2022, then rose by 5.81% to $29.5 million in 2023, then grew by 23.04% to $36.3 million in 2024, then increased by 5.55% to $38.3 million in 2025.
  • The last three reported values for Total Liabilities were $38.3 million (Q4 2025), $36.7 million (Q3 2025), and $36.4 million (Q2 2025) per Business Quant data.